Open Access System for Information Sharing

Login Library

 

Thesis
Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads
Full metadata record
Files in This Item:
There are no files associated with this item.
DC FieldValueLanguage
dc.contributor.author손산하en_US
dc.date.accessioned2014-12-01T11:49:12Z-
dc.date.available2014-12-01T11:49:12Z-
dc.date.issued2014en_US
dc.identifier.otherOAK-2014-01659en_US
dc.identifier.urihttp://postech.dcollection.net/jsp/common/DcLoOrgPer.jsp?sItemId=000001675764en_US
dc.identifier.urihttps://oasis.postech.ac.kr/handle/2014.oak/2161-
dc.descriptionMasteren_US
dc.description.abstractA network including collaborative R&D networks is the place where knowledge is diffused, shared, and evolves. In terms of Knowledge management, analyzing the network is important since it can detect how knowledge or information flows, diffuses or is shared in the certain network and thereby may provide helpful tips to enhance the efficiency and effectiveness of the network. In these days, numerous collaborative R&D networks or consortia have been emerged globally at diverse industrial and academic field in practice as international R&D collaboration has been highlighted. At the same time, discussions for more efficient and effective network have actively been done and network analysis such as SNA (Social Network Analysis) is considered as first step for those discussions. This paper therefore is designed to analyze real case of collaborative R&D network called IMI (Innovative Medicines Initiative) which is EU’s collaborative R&D program in pharmaceutical field. Through the social network analysis on IMI project consortia, this study try to observe the unique network properties of pharmaceutical collaborative R&D network.Based on the SNA, this study concludes major network property of IMI as a ‘disproportion network’ dominated by several multinational pharmaceutical companies with high centrality. Using the high centrality of pharmaceutical companies, this paper suggests strategy for network development which is mainly about consolidating functions of pharmaceutical companies in running IMI network.en_US
dc.languageengen_US
dc.publisher포항공과대학교en_US
dc.rightsBY_NC_NDen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.0/kren_US
dc.titleSocial Network Analysis on Collaborative R&D Consortia in Pharmaceutical Field: Topological Properties of EU’s Innovative Medicines Initiative (IMI) Networken_US
dc.typeThesisen_US
dc.contributor.college일반대학원 기술경영대학원과정en_US
dc.date.degree2014- 2en_US
dc.type.docTypeThesis-

qr_code

  • mendeley

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Views & Downloads

Browse